Presentation
7 March 2022 Antibody-target binding in living tumors using macroscopy fluorescence lifetime imaging
Author Affiliations +
Abstract
There is a continuing need to develop preclinical molecular imaging modalities to guide the development and optimization of targeted therapies in oncology. We have established Macroscopic Fluorescence Lifetime Imaging (MFLI) associated with Forster Resonance Energy Transfer (FRET) to report quantitatively on antibody-target engagement in live intact animals at the organ level. Here, we use FLI FRET imaging to quantify the binding of near infrared labeled antibody drugs to breast cancer cells or tumor xenografts. In combination with antibody engineering, this approach provides a robust analytical tool to optimize the binding and uptake of antibody-target binding during tumor progression and treatment.
Conference Presentation
© (2022) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Margarida Barroso, Alena Rudkouskaya, Jason Smith, John Williams, and Xavier Intes "Antibody-target binding in living tumors using macroscopy fluorescence lifetime imaging", Proc. SPIE PC11965, Multiphoton Microscopy in the Biomedical Sciences XXII, PC119650C (7 March 2022); https://doi.org/10.1117/12.2609024
Advertisement
Advertisement
KEYWORDS
Tumors

Fluorescence resonance energy transfer

Near infrared

Fluorescence lifetime imaging

Imaging systems

Microscopy

Resonance energy transfer

Back to Top